NYSE:BIO

Stock Analysis Report

Executive Summary

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally.

Snowflake

Fundamentals

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has Bio-Rad Laboratories's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.7%

BIO

0.2%

US Life Sciences

1.0%

US Market


1 Year Return

24.3%

BIO

14.5%

US Life Sciences

8.0%

US Market

Return vs Industry: BIO exceeded the US Life Sciences industry which returned 14.5% over the past year.

Return vs Market: BIO exceeded the US Market which returned 8% over the past year.


Shareholder returns

BIOIndustryMarket
7 Day2.7%0.2%1.0%
30 Day-0.5%-4.8%-0.07%
90 Day6.2%-5.2%-1.0%
1 Year24.3%24.3%14.7%14.5%10.4%8.0%
3 Year114.2%114.2%77.9%76.5%46.2%36.7%
5 Year204.0%204.0%112.2%102.6%64.3%46.2%

Price Volatility Vs. Market

How volatile is Bio-Rad Laboratories's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bio-Rad Laboratories undervalued compared to its fair value and its price relative to the market?

11.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: BIO ($343.54) is trading above our estimate of fair value ($192.24)

Significantly Below Fair Value: BIO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: BIO is good value based on its PE Ratio (11.3x) compared to the Life Sciences industry average (32.5x).

PE vs Market: BIO is good value based on its PE Ratio (11.3x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BIO is good value based on its PB Ratio (1.9x) compared to the US Life Sciences industry average (4.3x).


Next Steps

Future Growth

How is Bio-Rad Laboratories forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

6.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO's forecast earnings growth (6.5% per year) is above the savings rate (2.7%).

Earnings vs Market: BIO's earnings (6.5% per year) are forecast to grow slower than the US market (14.5% per year).

High Growth Earnings: BIO's earnings are forecast to grow, but not significantly.

Revenue vs Market: BIO's revenue (4.2% per year) is forecast to grow slower than the US market (7.2% per year).

High Growth Revenue: BIO's revenue (4.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bio-Rad Laboratories performed over the past 5 years?

57.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have grown significantly by 57.2% per year over the past 5 years.

Accelerating Growth: BIO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIO had negative earnings growth (-12.1%) over the past year, making it difficult to compare to the Life Sciences industry average (45%).


Return on Equity

High ROE: BIO's Return on Equity (16.5%) is considered low.


Return on Assets

ROA vs Industry: BIO has a higher Return on Assets than the Life Sciences industry average last year.


Return on Capital Employed

ROCE Improving: BIO's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Bio-Rad Laboratories's financial position?


Financial Position Analysis

Short Term Liabilities: BIO's short term assets ($2.1B) exceeds its short term liabilities ($446.0M)

Long Term Liabilities: BIO's short term assets (2.1B) exceeds its long term liabilities (1.7B)


Debt to Equity History and Analysis

Debt Level: BIO's debt to equity ratio (7.8%) is considered satisfactory

Reducing Debt: BIO's debt to equity ratio has reduced from 18.9% to 7.8% over the past 5 years.

Debt Coverage: BIO's debt is well covered by operating cash flow (85.5%).

Interest Coverage: BIO earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BIO has a low level of unsold assets or inventory.

Debt Coverage by Assets: BIO's debt is covered by short term assets (assets are 4.882390x debt).


Next Steps

Dividend

What is Bio-Rad Laboratories's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage0.4%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BIO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Bio-Rad Laboratories's salary, the management and board of directors tenure and is there insider trading?

4.1yrs

Average management tenure


CEO

Norman Schwartz (69yo)

16.8yrs

Tenure

US$7,639,414

Compensation

Mr. Norman D. Schwartz has been the Chief Executive Officer and President of Bio-Rad Laboratories, Inc. since January 1, 2003 and has been its Chairman since 2012. Mr. Schwartz served as Vice President of  ...


CEO Compensation Analysis

Compensation vs. Market: Norman's total compensation ($USD7.64M) is below average for companies of similar size in the US market ($USD11.18M).

Compensation vs Earnings: Norman's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


Management Age and Tenure

4.1yrs

Average Tenure

61yo

Average Age

Experienced Management: BIO's management team is considered experienced (4.1 years average tenure).


Board Age and Tenure

2.6yrs

Average Tenure

65yo

Average Age

Experienced Board: BIO's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: BIO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$172,26016 Sep 19
Annette Tumolo
EntityIndividual
Role
Senior Key Executive
Executive VP & President of Life Science Group
Shares522
Max PriceUS$330.00
SellUS$362,72305 Sep 19
Michael Crowley
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Global Commercial Operations
Shares1,089
Max PriceUS$333.08
SellUS$99,20014 Aug 19
Timothy Ernst
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares310
Max PriceUS$320.00
SellUS$104,00014 Aug 19
Michael Crowley
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Global Commercial Operations
Shares325
Max PriceUS$320.00
SellUS$249,88716 May 19
Timothy Ernst
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares845.73
Max PriceUS$299.31
SellUS$349,92817 Dec 18
Christine Tsingos
EntityIndividual
Shares1,411
Max PriceUS$248.00
SellUS$97,22815 Dec 18
Michael Crowley
EntityIndividual
Role
Senior Key Executive
Executive Vice President of Global Commercial Operations
Shares392
Max PriceUS$248.03
SellUS$216,04512 Dec 18
James Stark
EntityIndividual
Shares848
Max PriceUS$254.77
SellUS$298,70412 Dec 18
Annette Tumolo
EntityIndividual
Role
Senior Key Executive
Executive VP & President of Life Science Group
Shares1,176
Max PriceUS$254.00

Ownership Breakdown


Management Team

  • Norman Schwartz (69yo)

    Chairman

    • Tenure: 16.8yrs
    • Compensation: US$7.64m
  • John Goetz (69yo)

    Consultant

    • Tenure: 7.8yrs
    • Compensation: US$3.24m
  • Ilan Daskal (53yo)

    Executive VP & CFO

    • Tenure: 0.5yrs
  • Andy Last (59yo)

    Executive VP & COO

    • Tenure: 0.5yrs
  • Timothy Ernst (59yo)

    Executive VP

    • Tenure: 3.3yrs
  • John Hertia (63yo)

    Executive VP & President of Clinical Diagnostics Group

    • Tenure: 5.2yrs
    • Compensation: US$1.91m
  • Mike Crowley (57yo)

    Executive Vice President of Global Commercial Operations

    • Tenure: 4.8yrs
    • Compensation: US$1.81m
  • Annette Tumolo (64yo)

    Executive VP & President of Life Science Group

    • Tenure: 2.1yrs
    • Compensation: US$1.86m
  • Colleen Corey

    Senior Vice President of Global Human Resources

    • Tenure: 0yrs
  • Diane Dahowski

    Senior Vice President of Global Technology & Systems

    • Tenure: 0yrs

Board Members

  • Greg Hinckley (72yo)

    Lead Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$150.00k
  • Norman Schwartz (69yo)

    Chairman

    • Tenure: 16.8yrs
    • Compensation: US$7.64m
  • Alice Schwartz (92yo)

    Director

    • Tenure: 52.8yrs
    • Compensation: US$120.00k
  • Jeff Edwards (58yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$140.00k
  • Arnie Pinkston (60yo)

    Independent Director

    • Tenure: 2.5yrs
    • Compensation: US$130.00k
  • Melinda Pei (61yo)

    Independent Director

    • Tenure: 2.8yrs
    • Compensation: US$143.00k

Company Information

Bio-Rad Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Rad Laboratories, Inc.
  • Ticker: BIO
  • Exchange: NYSE
  • Founded: 1952
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$10.228b
  • Shares outstanding: 29.80m
  • Website: https://www.bio-rad.com

Number of Employees


Location

  • Bio-Rad Laboratories, Inc.
  • 1000 Alfred Nobel Drive
  • Hercules
  • California
  • 94547
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIO.BNYSE (New York Stock Exchange)Class B Common StockUSUSDOct 1974
BIONYSE (New York Stock Exchange)YesClass A Common StockUSUSDFeb 1980
BUWADB (Deutsche Boerse AG)YesClass A Common StockDEEURFeb 1980

Biography

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and intern ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 23:33
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.